Y-Mabs Therapeutics: Buy Rating Affirmed on Promising SADA Program Advancements and Market Expansion Potential

John Newman, an analyst from Canaccord Genuity, maintained the Buy rating on Y-Mabs Therapeutics (YMAB – Research Report). The associated price target remains the same with $26.00.

John Newman has given his Buy rating due to a combination of factors related to Y-Mabs Therapeutics’ advancements in their SADA program. The company is developing a new radiohapten, PROTEUS, which has shown promising results in preclinical models by significantly improving tumor uptake in neuroblastoma and small cell lung cancer. This enhancement in tumor targeting is expected to broaden patient selection and improve treatment efficacy, which is a positive indicator for the company’s future growth.
Moreover, the new PROTEUS radiohapten offers greater flexibility by accommodating multiple payloads across different categories, potentially expanding market opportunities for Y-Mabs. Although the optimization of the SADA program may extend the timeline, the long-term value driven by improved tumor uptake and payload flexibility supports a positive outlook. Consequently, John Newman maintains a Buy rating with a price target of $26, reflecting confidence in the company’s strategic direction and potential for market expansion.

In another report released yesterday, Clear Street also reiterated a Buy rating on the stock with a $17.00 price target.

YMAB’s price has also changed dramatically for the past six months – from $11.880 to $4.620, which is a -61.11% drop .